Anna did say they were going with NSCLC for 936 which is why I thought a possible combo with Merck. Im sure a lot of analysis goes into narrowing down to which target to go after, obviously results but also I think competition and what other drugs are doing against same target. TNBC was other target mentioned .
fwiw if results are good Im guessing they buy out 936 from Macrogenics (they seem to need money to fund other trials.
and so we wait